Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUNEPOTENT-CRP in Outpatients with Mild to Moderate COVID-19
NCT06676709Phase 2
Key facts
- Status
- Completed
- Start
- Apr 2021
- Primary completion
- Feb 2022
- Countries
- 1
- Sponsor
- Universidad Autónoma de Nuevo León
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Drugs
- IMMUNEPOTENT-CRP
- Conditions
- coronavirus disease 2019 (COVID-19)
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing I-CRP group with Placebo control (2 arms). Primary endpoint: Cytokine and Chemokine Serum Levels Evaluation at Day 14. Started Apr 2021; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
I-CRP group
IMMUNEPOTENT-CRP (I-CRP) 5 U/vial.
Placebo control
Placebo (corn starch extract).
03
Who it enrols
Adult outpatients with mild to moderate COVID-19 and confirmed SARS-CoV-2 infection. Excludes patients with immunosuppression, autoimmune disease, history of malignancy, or those receiving chemotherapy.
04
Endpoints
Primary
Cytokine and Chemokine Serum Levels Evaluation
Secondary
Lactate Dehydrogenase Levels
High-Sensitivity C-Reactive Protein Levels
Ferritin Levels
D-Dimer Levels
Lymphocyte Subpopulations
SARS-CoV-2 Infection Status Evaluation
Beyond the preview
Go deeper on NCT06676709.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06676709.